At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRKR Marker Therapeutics, Inc.
Trading 12-26 11:57:44 EST
3.32
-0.06
-1.78%
High3.55
Low3.32
Vol23.25K
Open3.45
D1 Closing3.38
Amplitude6.95%
Mkt Cap35.55M
Tradable Cap26.01M
Total Shares10.71M
T/O78.93K
T/O Rate0.30%
Tradable Shares7.84M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Marker Therapeutics to Raise $16.1 Million in Private Placement
Marker Therapeutics Awarded $9.5 Million Grant From the Cancer Prevention & Research Institute of Texas (Cprit) to Support the Investigation of Mt-601 in Patients With Pancreatic Cancer
Press Release: Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.